T. Murate

Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.

M. Ichihara, Y. Kawamoto, Y. Nozawa, 2020, Biochemical and biophysical research communications.

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.

M. Narabayashi, Y. Kagami, M. Ogura, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.

M Taniwaki, M. Taniwaki, Y. Ohashi, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.